The APOL1 Long-Term Kidney Transplantation Outcomes Network-APOLLO.

Molecular genetics has altered our understanding of the epidemiology and treatment of CKD; >30% of blacks with ESKD have apoL1 gene ( APOL1 )–associated disorders, including FSGS, HIV-associated nephropathy, sickle cell nephropathy, severe lupus nephritis, and solidified glomerulosclerosis with

[1]  A. Garg,et al.  APOL1 Genotype and Renal Function of Black Living Donors. , 2018, Journal of the American Society of Nephrology : JASN.

[2]  B. Freedman,et al.  Apolipoprotein L1 Gene Effects on Kidney Transplantation. , 2017, Seminars in nephrology.

[3]  S. Fullerton,et al.  Clinical Genetic Testing for APOL1: Are we There Yet? , 2017, Seminars in nephrology.

[4]  A. Israni,et al.  Effect of Replacing Race With Apolipoprotein L1 Genotype in Calculation of Kidney Donor Risk Index , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[5]  J. Schold,et al.  Integrating APOL1 Gene Variants Into Renal Transplantation: Considerations Arising From the American Society of Transplantation Expert Conference , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[6]  Bertram L Kasiske,et al.  New national allocation policy for deceased donor kidneys in the United States and possible effect on patient outcomes. , 2014, Journal of the American Society of Nephrology : JASN.

[7]  C. Young,et al.  African American living-kidney donors should be screened for APOL1 risk alleles. , 2011, Transplantation.

[8]  C. Winkler,et al.  Association of Trypanolytic ApoL1 Variants with Kidney Disease in African Americans , 2010, Science.

[9]  F. Port,et al.  Effect of waiting time on renal transplant outcome. , 2000, Kidney international.